Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Not yet recruiting × Temozolomide × Clear all

Phase

Phase 2 8 Phase 3 5 Phase 1/2 5 Phase 1 2 Phase 2/3 1

Status

Completed 4 Unknown 3 Recruiting 2 Active not recruiting 2 Withdrawn 1 Terminated 1 Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Interventions

Cisplatin 8 Carboplatin 7 Oxaliplatin 5 Fluorouracil 5 Capecitabine 5 Drug Therapy 4 130-nm albumin-bound paclitaxel 4 venetoclax 3 pembrolizumab 3 Trastuzumab 3 Radiotherapy 3 Gemcitabine 3 trametinib 2 sintilimab 2 pertuzumab 2 dabrafenib 2 camrelizumab 2 apatinib 2 Surgical Procedures, Operative 2 Radiosurgery 2 Pemetrexed 2 Neoadjuvant Therapy 2 Leucovorin 2 Docetaxel 2 Androgen Antagonists 2 tucatinib 1 tegafur-gimeracil-oteracil 1 regorafenib 1 osimertinib 1 nimotuzumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07349693 2026-01-20

Cerebraca-02/3

Everfront Biotech Co., Ltd.

Phase 2/3 Not yet recruiting

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡